Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
Disclosed herein are formulations suitable for parenteral administration of certain hydrophobic active agents such as Coenzyme Q10. Methods of preparing the same and methods of treatment of oncological disorders using the same are also provided herein. The formulations comprise an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent and an opsonization reducer wherein the colloidal nano-dispersion of the active agent is dispersed into nano-dispersion particles having a mean size of less than 200-nm. Methods of preparing the parenteral formulations comprise dispersing the hydrophobic active agent by high pressure homogenization by (1) adding hydrophobic active agent to a 65° C. bath of water and mixing to form a hydrophobic active agent/water mixture; (2) adding a dispersion stabilizing agent to the hydrophobic active agent/water mixture and mix at 65° C. to form a hydrophobic active agent/water/stabilizer mixture; (3) adding an opsonization reducer to form a hydrophobic active agent/water/stabilizer/reducer mixture; (4) pre-heating a Microfluidizer to 65° C.; and (5) processing by mixing the hydrophobic active agent/water/stabilizer/reducer mixture in the Microfluidizer at 65° C. such that a hydrophobic active agent colloidal nano-dispersion having a mean particle size less than 200-nm is formed. Provided herein are also methods of treating oncological disorders by administering formulations described herein to a subject such that treatment or prevention of the oncological disorder occurs.
1. A therapeutic formulation suitable for intravenous administration to a subject comprising:
an aqueous solution;
coenzyme Q10;
dimyristoylphosphatidyl choline; and
poloxamer 188;
wherein the coenzyme Q10 is dispersed into a colloidal nano-dispersion of particles having a mean size of less than 50 nm; wherein the coenzyme Q10 is present in said formulation in an amount of 4 wt %; wherein the dimyristoylphosphatidyl choline is present in said formulation in an amount of 3 wt %; and wherein the poloxamer 188 is present in said formulation in an amount selected from the group consisting of: 0.5 wt %, 1.0 wt % and 1.5 wt %.
2. The formulation of claim 1 , wherein the colloidal nano-dispersion is a suspension or an emulsion.
3. The formulation of claim 1 , wherein the coenzyme Q10 of the colloidal nano-dispersion is in a crystalline form.
4. The formulation of claim 1 , wherein the coenzyme Q10 of the colloidal nano-dispersion is in a super-cooled melt form.
5. The formulation of claim 1 , wherein the formulation has a wt % of the coenzyme Q10, dimyristoylphosphatidyl choline and poloxamer 188 of 4%, 3% and 1.5%, respectively.
6. The formulation of claim 1 , wherein the mean size of the nano-dispersion particles is between 35-nm and 40-nm.
7. The formulation of claim 1 , wherein the mean size of the nano-dispersion particles is less than 45-nm.
8. A therapeutic formulation suitable for intravenous administration to a subject comprising:
an aqueous solution;
coenzyme Q10 dispersed to form a colloidal nano-dispersion of particles;
dimyristoylphosphatidyl choline; and
poloxamer 188;
wherein the coenzyme Q10 is dispersed into liposomes having a mean size of less than 50 nm; wherein the coenzyme Q10 is present in said formulation in an amount of 4 wt %; wherein the dimyristoylphosphatidyl choline is present in said formulation in an amount of 3 wt %, and wherein the poloxamer 188 is present in said formulation in an amount selected from the group consisting of: 0.5 wt %, 1.0 wt % and 1.5 wt %.
9. The formulation of claim 8 , wherein the liposomes are bi-layered multilamellar liposomes having an aqueous space between the bi-layers and a lipophilic space within the bi-layers.
10. The formulation of claim 9 , wherein the coenzyme Q10 is entrapped within the lipophilic space of the bi-layers.
11. The formulation of claim 9 , wherein the multilamellar liposome further includes a hydrophilic agent entrapped in the aqueous space between the bi-layers.
12. The formulation of claim 8 , wherein the colloidal nano-dispersion is a suspension or an emulsion.
13. The formulation of claim 8 , wherein the coenzyme Q10 of the colloidal nano-dispersion is in a crystalline form.
14. The formulation of claim 8 , wherein the coenzyme Q10 of the colloidal nano-dispersion is in a super-cooled melt form.
15. A therapeutic formulation suitable for intravenous administration to a subject comprising:
an aqueous solution;
coenzyme Q10;
dimyristoylphosphatidyl choline; and
poloxamer 188;
wherein the coenzyme Q10 is dispersed into a colloidal nano-dispersion of particles having a mean size of less than 50 nm, wherein the coenzyme Q10 is present in said formulation in an amount of 4 wt %; wherein the dimyristoylphosphatidyl choline is present in said formulation in an amount of 3 wt %; and wherein the ratio of the coenzyme Q10, the dimyristoylphosphatidyl choline and the poloxamer 188 is 4:3:0.5-1.5, respectively.
16. A method of preparing the therapeutic formulation of claim 1 , wherein the method comprises dispersing the coenzyme Q10 by high pressure homogenization by:
adding the coenzyme Q10 to a 65° C. bath of water and mixing to form a hydrophobic active agent/water mixture;
adding dimyristoylphosphatidyl choline to the coenzyme Q10/water mixture and mixing at 65° C. to form a coenzyme Q10/water/dimyristoylphosphatidyl choline mixture;
adding poloxamer 188 to form a coenzyme Q10/water/dimyristoylphosphatidyl choline reducer mixture;
pre-heating a homogenizer to 65° C.; and
processing by mixing the coenzyme Q10/water/dimyristoylphosphatidyl choline/reducer mixture in the homogenizer at 65° C. such that a coenzyme Q10 colloidal nano-dispersion having a mean particle size of less than 50 nm is formed, and wherein the dimyristoylphosphatidyl choline is present in said formulation in an amount of 3 wt %.
17. A therapeutic formulation of claim 1 , prepared by the method of claim 16 .
18. The method of claim 16 , wherein the coenzyme Q10 of the colloidal nano-dispersion is in the form of a super-cooled melt.
19. The method of claim 16 , wherein the formulation has a wt % of the coenzyme Q10, DMPC and poloxamer 188 of 4%, 3% and 1.5%, respectively.
20. The method of claim 16 , wherein a coenzyme Q10 colloidal nano-dispersion having a mean particle size of between 35-nm and 40-nm is formed.
21. The method of claim 16 , wherein a coenzyme Q10 colloidal nano-dispersion having a mean particle size of less than 45-nm is formed.
22. The method of claim 16 , further comprising the step of lyophilizing the colloidal nano-dispersion to crystallize the coenzyme Q10 colloidal nano-dispersion particles.
23. The method of claim 22 , further comprising the step of adding a lyoprotectant.
24. The method of claim 23 , wherein the lyoprotectant is a nutritive sugar selected from the group consisting of lactose, mannose, maltose, galactose, fructose, sorbose, raffinose, neuraminic acid, glucosamine, galactosamine, N-methylglucosamine, mannitol, sorbitol, arginine, glycine and sucrose.
25. The formulation of claim 15 , wherein the colloidal nano-dispersion is a suspension or an emulsion.
26. The formulation of claim 15 , wherein the coenzyme Q10 of the colloidal nano-dispersion is in a crystalline form.
27. The formulation of claim 15 , wherein the coenzyme Q10 of the colloidal nano-dispersion is in a super-cooled melt form.
28. The formulation of claim 15 , wherein the formulation has a wt % of the coenzyme Q10, dimyristoylphosphatidyl choline and poloxamer 188 of 4%, 3% and 1.5%, respectively.
29. The formulation of claim 15 , wherein the mean size of the nano-dispersion particles is between 35-nm and 40-nm.
30. The formulation of claim 15 , wherein the mean size of the nano-dispersion particles is less than 45-nm.